NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NEI E-153-2020-0-US-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells US National Stage 18/290,396 Pending
NCI E-264-2011-0-US-02 DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS US CON 18/507,690 Pending
NIA E-062-2021-0-EP-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE EP National Stage 22722061.3 Pending
NEI E-153-2020-0-AU-03 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells AU National Stage 2022282379 Pending
NEI E-155-2020-0-AU-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS AU National Stage 2022280062 Pending
NHLBI E-127-2021-2-US-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES US National Stage 18/560,035 Pending
NHLBI E-166-2022-0-PC-01 MYOTOMY CATHETER SYSTEM AND METHODS FOR A MYOTOMY CATHETER SYSTEM PCT PCT PCT/US2023/079114 Pending
NCI E-009-2023-0-PC-01 IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OFCANCER AND MYELOID-MEDIATED DISEASES PCT PCT PCT/US2023/078854 Pending
NCI E-017-2023-0-PC-01 Directed acetylation of mRNA through engineered snoRNA adapters PCT PCT PCT/US2023/078830 Pending
NCI E-101-2021-0-JP-02 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 JP National Stage 2023-568469 Pending
NHLBI E-127-2021-2-IL-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES IL National Stage 308337 Pending
NCI E-101-2021-0-US-07 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 US National Stage 18/289,596 Pending
NCI E-291-2012-0-US-25 M971 CHIMERIC ANTIGEN RECEPTORS US CON 18/503,107 Pending
NCI E-291-2012-0-US-26 M971 CHIMERIC ANTIGEN RECEPTORS US CON 18/502,993 Pending
NIAID E-149-2022-0-PC-01 NOVEL ANTIBODIES FOR HIV AND METHODS OF MAKING AND USING SAME PCT PCT PCT/US2023/078631 Pending
NCI E-172-2020-0-HK-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION HK EP 62023081975.2 Pending
NCI E-105-2023-0-US-01 DNA methylation-based cancer diagnostics for tumors of the central nervous system, kidney and hematopoietic system US ORD 18/499,833 Pending
NCI E-118-2021-0-AU-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors AU National Stage 2022291120 Pending
NCI E-285-2016-2-US-01 Glypican 2 As A Cancer Marker And Therapeutic Target US DIV 18/499,054 Pending
NIAID E-153-2023-0-PC-01 Rebalancing the Immune System Through Depletion of Myeloid-Biased Hematopoietic Stem Cells PCT PCT PCT/US2023/036280 Pending
NCI E-206-2022-0-PC-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PCT PCT PCT/US2023/078190 Pending
NCI E-213-2022-0-PC-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PCT PCT PCT/US2023/078156 Pending
NCI E-101-2021-0-CA-03 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 CA National Stage 3217263 Pending
NIAID E-239-2020-0-CN-01 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE CN National Stage 202280031803.6 Pending
NIAID E-139-2006-0-AU-01 Development Of Dengue Virus Vaccine Components AU DIV 2023255035 Pending
NCI E-099-2021-0-US-02 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE US National Stage 18/557,741 Pending
NIAID E-089-2022-0-US-03 PREFUSION-STABILIZED LASSA VIRUS GLYCOPROTEIN COMPLEX AND ITS USE US National Stage 18/557,396 Pending
NIAID E-174-2023-0-US-02 Self-Assembling Nanoparticles US ORD 18/494,491 Pending
NIAID E-221-2022-2-US-01 LENTIVIRAL VECTORS USEFUL FOR THE TREATMENT OF DISEASE US National Stage 18/288,358 Pending
NIAID E-174-2023-0-PC-01 Self-Assembling Nanoparticles PCT PCT PCT/US2023/077767 Pending
NIAID E-025-2023-0-PC-01 Combination Treatment For Treating Cancer PCT PCT PCT/US2023/077765 Pending
NCI E-165-2020-0-HK-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation HK EP 62023081216.1 Pending
NCI E-065-2021-0-AU-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF AU National Stage 2022241765 Pending
NIAID E-002-2023-2-PC-01 Vesicular Stomatitis Virus-Based Sudan Virus Vaccine PCT PCT PCT/US2023/077444 Pending
NIAID E-228-2016-1-US-01 STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF US CON 18/491,193 Pending
NICHD E-058-2021-0-JP-01 La Protein As A Novel Regulator Of Osteoclastogenesis JP National Stage 2023-553206 Pending
NIA E-062-2021-0-US-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE US National Stage 18/287,630 Pending
NIAMS E-244-2020-0-CN-01 SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2 CN National Stage 202280029673.2 Issued
NIA E-197-2022-0-PC-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PCT PCT PCT/US2023/077173 Pending
NIAID E-018-2018-0-JP-11 CHIMERIC VECTORS JP DIV 2023-179912 Pending
NCI E-118-2021-0-EP-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors EP National Stage 22738126.6 Pending
NIAID E-239-2020-0-IN-01 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE IN National Stage 202317071027 Pending
NCI E-344-2013-0-AU-02 TEM8 Antibodies and Their Use AU DIV 2023251389 Pending
NCI E-065-2021-0-EP-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF EP National Stage 22719666.4 Pending
NCI E-191-2019-0-US-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION US National Stage 18/286,911 Pending
NCI E-216-2022-0-PC-01 METHODS OF IDENTIFYING TARGETS OF CANCER DRUGS
AND OF TREATING CANCER 		PCT PCT PCT/US2023/076704 Pending
NIAID E-239-2020-0-US-02 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE US National Stage 18/555,137 Pending
NIAID E-064-2016-1-AU-01 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE AU DIV 2023248085 Pending
NIAID E-239-2020-0-CA-01 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE CA National Stage 3216466 Pending
NIAID E-037-2021-1-CN-06 Antibodies Targeting The Spike Protein Of Coronaviruses CN National Stage 202280027556.2 Pending